CytomX Therapeutics, Inc. (CTMX) stock
CTMXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.04+0.00 (0.00%)
Close on Nov 13, 2026Market cap $444.52MP/E –Yield –
CytomX Therapeutics cash
Cash and short-term investments held at the end of each period.
CytomX Therapeutics's cash was $347.98M at Sep 30, 2026. For fiscal 2025 it was $137.05M, up 34.5% from the year before. Over ten years it grew -3.0% a year on average. The highest annual figure on record is $436.13M in fiscal 2018.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $137.05M | +34.5% |
| FY2024 | Dec 31, 2024 | $101.87M | -41.9% |
| FY2023 | Dec 31, 2023 | $175.36M | +83.5% |
| FY2022 | Dec 31, 2022 | $95.57M | -64.1% |
| FY2021 | Dec 31, 2021 | $266.35M | +3.9% |
| FY2020 | Dec 31, 2020 | $256.30M | -8.3% |
| FY2019 | Dec 31, 2019 | $279.39M | -35.9% |
| FY2018 | Dec 31, 2018 | $436.13M | +16.6% |
| FY2017 | Dec 31, 2017 | $374.11M | +105.7% |
| FY2016 | Dec 31, 2016 | $181.90M | -2.6% |
| FY2015 | Dec 31, 2015 | $186.70M | +189.9% |
| FY2014 | Dec 31, 2014 | $64.40M | +640.0% |
| FY2013 | Dec 31, 2013 | $8.70M | -41.0% |
| FY2012 | Dec 31, 2012 | $14.75M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $347.98M | +142.3% |
| Q2 FY2026 | Jun 30, 2026 | $330.28M | +108.9% |
| Q1 FY2026 | Mar 31, 2026 | $346.71M | +333.9% |
| Q4 FY2025 | Dec 31, 2025 | $137.05M | +34.5% |
| Q3 FY2025 | Sep 30, 2025 | $143.63M | +21.1% |
| Q2 FY2025 | Jun 30, 2025 | $158.09M | +14.4% |
| Q1 FY2025 | Mar 31, 2025 | $79.90M | -48.1% |
| Q4 FY2024 | Dec 31, 2024 | $101.87M | -41.9% |
| Q3 FY2024 | Sep 30, 2024 | $118.63M | -39.3% |
| Q2 FY2024 | Jun 30, 2024 | $138.19M | -24.2% |
| Q1 FY2024 | Mar 31, 2024 | $154.09M | -25.1% |
| Q4 FY2023 | Dec 31, 2023 | $175.36M | +83.5% |
| Q3 FY2023 | Sep 30, 2023 | $195.37M | +10.7% |
| Q2 FY2023 | Jun 30, 2023 | $182.36M | +3.8% |
| Q1 FY2023 | Mar 31, 2023 | $205.86M | -8.8% |
| Q4 FY2022 | Dec 31, 2022 | $95.57M | -64.1% |
| Q3 FY2022 | Sep 30, 2022 | $176.44M | -25.3% |
| Q2 FY2022 | Jun 30, 2022 | $175.67M | -34.0% |
| Q1 FY2022 | Mar 31, 2022 | $225.69M | -34.8% |
| Q4 FY2021 | Dec 31, 2021 | $266.35M | +3.9% |
| Q3 FY2021 | Sep 30, 2021 | $236.29M | -20.2% |
| Q2 FY2021 | Jun 30, 2021 | $266.18M | -10.1% |
| Q1 FY2021 | Mar 31, 2021 | $346.25M | +53.4% |
| Q4 FY2020 | Dec 31, 2020 | $256.30M | -8.3% |
| Q3 FY2020 | Sep 30, 2020 | $296.13M | -9.1% |
| Q2 FY2020 | Jun 30, 2020 | $296.14M | -15.2% |
| Q1 FY2020 | Mar 31, 2020 | $225.78M | -43.1% |
| Q4 FY2019 | Dec 31, 2019 | $279.39M | -35.9% |
| Q3 FY2019 | Sep 30, 2019 | $325.71M | +25.4% |
| Q2 FY2019 | Jun 30, 2019 | $349.14M | +162.7% |
| Q1 FY2019 | Mar 31, 2019 | $396.60M | +179.0% |
| Q4 FY2018 | Dec 31, 2018 | $436.13M | +16.6% |
| Q3 FY2018 | Sep 30, 2018 | $259.75M | -21.6% |
| Q2 FY2018 | Jun 30, 2018 | $132.91M | -60.4% |
| Q1 FY2018 | Mar 31, 2018 | $142.16M | -12.5% |
| Q4 FY2017 | Dec 31, 2017 | $374.11M | +105.7% |
| Q3 FY2017 | Sep 30, 2017 | $331.30M | – |
| Q2 FY2017 | Jun 30, 2017 | $335.90M | – |
| Q1 FY2017 | Mar 31, 2017 | $162.50M | – |
| Q4 FY2016 | Dec 31, 2016 | $181.90M | – |
See a number that looks wrong?